Research Article
Fibrosis-4 Model Influences Results of Patients with Hepatocellular Carcinoma Undergoing Hepatectomy
Table 1
Characteristics of the included patients.
| | Parameters | N(%) |
| | Male | 668 (84.8%) | | Age (years) (Mean ± SD) | 51.1±11.9 | | Etiology | | | HBV | 665 (84.4%) | | HCV | 14 (1.8%) | | NBNC | 109 (13.8%) | | Child-Pugh Score | | | A | 746 (94.7%) | | B | 42 (5.3%) |
| | MELD, median (IQR) | 8 (7-10) | | AST (U/L) (Mean ± SD) | 51.1±38.6 | | ALT (U/L) (Mean ± SD) | 49.8±40.6 | | Total bilirubin (umol/L) (Mean ± SD) | 16.2±13.7 | | Albumin (g/L) (Mean ± SD) | 41.2±4.4 | | INR (Mean ± SD) | 1.27±0.15 | | PLT (109/L) (Mean ± SD) | 140±70 | | Ishak | | | 0-2 | 282 (35.8%) | | 3-4 | 95 (12.1%) | | 5-6 | 411 (52.2%) | | Cirrhosis | 411 (52.2%) | | AFP (ng/mL) (Mean ± SD) | 10 (7.4%) | | BCLC | | | 0-A | 537 (68.2%) | | B | 117 (14.8%) | | C | 134 (17.0%) | | Tumor | | | Single | 636 (80.7%) | | Multiple | 152 (19.3%) | | Macrovascular invasion | 93 (11.8%) | | Microvascular Invasive | 162 (20.6%) | | Differentiation Degree | | | Poor | 89 (11.3%) | | Moderate | 680 (86.3%) | | Well | 19 (2.4%) | | Recurrent Hepatocellular Carcinoma | 37 (4.7%) | | Complications III-V | 68 (8.6%) | | Transfusion | 175 (22.2%) | | Hospital Stay (days) median (IQR) | 9 (7-11) | | AST/ALT (Mean ± SD) | 1.2±1.0 | | APRI (Mean ± SD) | 1.2±1.7 | | FIB-4 (Mean ± SD) | 3.6±3.7 | | Lok (Mean ± SD) | 12.6±1.6 | | King Score (Mean ± SD) | 33.1±43.7 |
|
|
ALT: alanine aminotransferase; AST: aspartate aminotransferase. AFP: α-fetoprotein; BCLC: Barcelona Clinic Liver Cancer; INR: international normalized ratio; PLT: platelet count. APRI: AST-to-platelet ratio Index; HBV: hepatitis B virus; HCV: hepatitis C virus; NBNC: non-B non-C hepatitis virus. MELD: model for end-stage liver disease; IQR: interquartile range; SD: standard deviation.
|
